Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 11, 2019

View Archived Issues

CD7 could target CAR T cells to AML

Long life in the SLO lane

Cross-species analysis identifies NSD2 as a key regulator of metastatic prostate cancer progression

Design and synthesis of novel imidazole-biaryl-tetrazole-based GSNOR inhibitors for COPD

Preclinical data presented for sarecycline for the treatment of acne vulgaris

Roche presents cannabinoid CB2 receptor inverse agonists

Phase III JEWEL study of lurasidone meets primary endpoint in patients with schizophrenia

Pfizer identifies muscarinic M4 receptor PAMs

Takeda Pharmaceutical divulges muscarinic M1 receptor PAMs

Common mechanism links diverse anemias

Protagonist Therapeutics initiates phase II study of PTG-300 in patients with beta-thalassemia

Bristol-Myers Squibb presents phase II data for pegbelfermin in non-alcoholic steatohepatitis

Patient enrollment ongoing in first in human trial of CPI-100

Novel piperazinyl pyrrolidin-2-ones reversibly inhibiting MGL

Blade Therapeutics patents calpain inhibitors

Regulator of calcineurin 1 suppresses nonshivering thermogenesis by two different mechanisms

First subject dosed in phase I study of the anti-AXL antibody BGB-149

Mitokinin discloses new PINK1 modulators

Pluristem reports successful case study in treatment of Buerger's disease patient

miRagen Therapeutics reports new phase I data on cobomarsen in CTCL, ATLL and DLBCL

OncoImmune completes phase II study of CD24Fc for acute GvHD prophylaxis

Beijing InnoCare begins first-in-human study of ICP-192 in advanced solid tumors

Theravance opens phase III study of TD-9855 to treat symptomatic neurogenic orthostatic hypotension

Regeneron initiates phase I/II study of REGN-5458 in relapsed or refractory multiple myeloma

First-in-human trial investigates RIPK1 inhibitor GSK-3145095 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...